Loading clinical trials...
Loading clinical trials...
This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Gilead Sciences
NCT01875588 · HIV Positive
NCT06857071 · Undiagnosed HIV Infection, Populations That Are Reluctant to Test for HIV, and more
NCT06598397 · Human Immunodeficiency Virus (HIV), Smoking Cessation
NCT06627764 · Substance Abuse, Intimate Partner Violence (IPV), and more
NCT07509853 · HIV Prevention, Substance Use, and more
Birmingham, Alabama
Los Angeles, California
Newport Beach, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions